Loading
  • Home
  • About
    • Our Leadership
    • Board of Directors
    • Investors
  • Pipeline & Science
    • Pipeline
    • Science
    • Clinical Trials
    • Expanded Access
    • Posters & Presentations
  • News
  • Careers
    • Open Positions
    • Benefits
  • Contact
  • Menu Menu

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate

June 3, 2025

Read more
/wp-content/uploads/logo.svg 0 0 eallison /wp-content/uploads/logo.svg eallison2025-06-02 15:17:232025-06-02 20:21:52Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate

Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate

May 22, 2025

Read more
/wp-content/uploads/logo.svg 0 0 eallison /wp-content/uploads/logo.svg eallison2025-05-21 15:38:022025-05-21 17:42:09Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate

Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-023 (ARTS-023), a Potential Best-in-Class, Novel CDK4 Selective Inhibitor

May 21, 2025

Read more
/wp-content/uploads/logo.svg 0 0 eallison /wp-content/uploads/logo.svg eallison2025-05-20 16:56:382025-05-21 13:14:19Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-023 (ARTS-023), a Potential Best-in-Class, Novel CDK4 Selective Inhibitor

Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate

January 7, 2025

Read more
/wp-content/uploads/logo.svg 0 0 David Anderson /wp-content/uploads/logo.svg David Anderson2025-01-06 13:56:552025-01-06 13:57:31Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate

Avenzo Therapeutics Announces Appointment of Patrick Machado, J.D. to Board of Directors as Independent Director

November 20, 2024

Read more
/wp-content/uploads/logo.svg 0 0 David Anderson /wp-content/uploads/logo.svg David Anderson2024-11-20 16:14:052024-11-20 16:14:05Avenzo Therapeutics Announces Appointment of Patrick Machado, J.D. to Board of Directors as Independent Director

Avenzo Therapeutics Provides Corporate Update and Announces Closing of Series A/A-1 Financing

November 18, 2024

Read more
/wp-content/uploads/logo.svg 0 0 David Anderson /wp-content/uploads/logo.svg David Anderson2024-11-20 16:13:322024-11-20 16:13:32Avenzo Therapeutics Provides Corporate Update and Announces Closing of Series A/A-1 Financing

Avenzo Therapeutics Honored by Goldman Sachs for Entrepreneurship

October 16, 2024

Read more
/wp-content/uploads/logo.svg 0 0 David Anderson /wp-content/uploads/logo.svg David Anderson2024-10-16 06:44:222024-10-16 06:45:50Avenzo Therapeutics Honored by Goldman Sachs for Entrepreneurship

Avenzo Therapeutics Announces Appointment of Garry Nicholson to Board of Directors as Independent Director

October 1, 2024

Read more
/wp-content/uploads/logo.svg 0 0 David Anderson /wp-content/uploads/logo.svg David Anderson2024-09-30 13:02:212024-09-30 13:02:21Avenzo Therapeutics Announces Appointment of Garry Nicholson to Board of Directors as Independent Director

Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer

September 3, 2024

Read more
/wp-content/uploads/logo.svg 0 0 David Anderson /wp-content/uploads/logo.svg David Anderson2024-08-30 12:45:582024-09-04 16:15:18Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer

Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline

March 26, 2024

Read more
/wp-content/uploads/logo.svg 0 0 eallison /wp-content/uploads/logo.svg eallison2024-03-22 13:38:572024-03-25 17:50:43Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline
Page 2 of 3123
© 2026 Avenzo Therapeutics, Inc. All Rights Reserved. | Terms of Service | Privacy Notice |
Cookie Preferences
  • Link to LinkedIn
Scroll to top Scroll to top Scroll to top

We use third-party services to help us understand how visitors use our website and improve performance. These cookies are optional and will only be enabled if you choose to accept them. You can change your selection at any time.

Accept settingsHide notification onlySettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services
Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Accept settingsHide notification only
Open Message Bar Open Message Bar Open Message Bar